Bone Abstracts

Molecules secreted by the osteoclast or ‘clastokynes’ are essential to stimulate bone formation by osteoblasts. Treatments with bisphosphates and Denosumab target osteoclast survival and differentiation. This suppresses bone turnover and is suspected to increase the risk of atypical fractures in the long term. A solution to overcome this is to develop strategies that target selectively the activity of osteoclasts without affecting their survival or differentiation. S...

The coupling of bone formation to bone resorption during treatment of postmenopausal osteoporosis with antiresorbers might be related to changes in Wnt/β-catenin signalling. We compared the effects of two bisphosphonate treatments on two Wnt inhibitors sclerostin (SOST) and Dickkopf-related protein 1 (DKK1). The study population included 72 women with postmenopausal osteoporosis participating simultaneously in two multicenter, placebo controlled trials. The patients were ...

Background: Zoledronic acid (ZA) is associated with a transient post-infusional acute phase reaction (APR) due to the activation of γδTCR lymphocytes (γδTcells).Aims: To investigate if APR correlates with γδTcell percentage or cytokine polarization, or with 25-OH vitamin D levels; to identify a 25-OH vitamin D level associated with a lower risk of APR.Methods: Sera for ELISA test (IFNγ, IL17, and ...

Bisphosphonate treatment reduces fracture risk in women with postmenopausal osteoporosis. However, some patients have an inadequate response to treatment. Estradiol and sclerostin play an important role in bone metabolism. Sclerostin is an endogenous inhibitor of osteoblastic activity and estrogen deficiency increases osteoclast activity and bone resorption.We examined the influence of both measures on fracture incidence in postmenopausal osteoporosis in...

Introduction: Prostaglandin E2 has bone-anabolic effects through EP4 receptor but its clinical utility is hindered by gastrointestinal side effects. To avoid these side effects, EP4 agonists (EP4a) were covalently linked to the bisphosphonate alendronate (ALN) to create two ALN-EP4a conjugate drugs, C1 and C2. When administered systemically, C1 and C2 will be target delivered to bone through ALN, where local hydrolytic enzymes liberate EP4a from ALN to exert bone an...

Background: Allopurinol reduces oxidative stress and interacts with purinergic signalling systems important in bone metabolism and muscle function. We assessed whether allopurinol use was associated with a reduced incidence of hip fracture in older people who had undergone rehabilitation.Methods: Analysis of prospective, routinely-collected rehabilitation and hospitalisation data. Data on patients discharged from a single inpatient geriatric rehabilitati...

Background: Resveratrol (RSV) is a natural polyphenolic compound, found in fx grapes, which possesses anti-inflammatory properties. RSV inhibits osteoclast activity and promotes osteoblastogenesis in vitro. Furthermore, RSV protects against bone loss after ovarectomy and immobilization in animal models. RSV treatment of obese men for 4 weeks resulted in an increase in bone specific alkaline phosphatase (BAP).Hypothesis: Low-grade inflammation is...

Objectives: To investigate the burden and impact of gastrointestinal (GI) events in osteoporosis (OP) patients by i) examining the association of GI events with the likelihood of OP treatment initiation; ii) measuring the effect of GI events on treatment discontinuation; and iii) determining the impact of GI events post-OP treatment on health care resource utilization and cost. All subjects are identified utilizing national health registries which cover the whole Danish popula...

It has been previously reported that prolonged treatment with rhPTH(1–34) or rhPTH(1–84) in rats is associated with the development of bone neoplasms including osteosarcomas. However, to date there has been no evidence of an increased osteosarcoma risk of in patients treated with rhPTH(1–34) or rhPTH(1–84), or in diseases associated with chronic PTH elevation. Abaloparatide (ABL) is a novel analog of PTHrP(1–34) currently being developed as a treatment...

Objective: This multi-objective prospective observational study is intended to examine treatment patterns, occurrence of gastrointestinal (GI) complications and clinical and health outcomes in post-menopausal women with osteoporosis (OP) in Europe and Canada. This abstract presents the baseline results of the treated population.Materials and methods: Post-menopausal osteoporotic women currently on treatment completed surveys intended to measure the incid...

Activin is a known physiologic regulator of bone metabolism. Ovariectomy-induced osteopenia has been shown to be attenuated by injection of the activin type IIA decoy receptor (ActRIIA-Fc). However, immobilization-induced osteopenia is driven by different pathways than ovariectomy-induced osteopenia, and the role of activin in immobilization-induced osteopenia has not yet been elucidated.The purpose of the study was to investigate the possible attenuatio...

In the recent years the role of the skeleton in glucose and energy homeostasis has been studied. In particular the osteoblast-specific protein osteocalcin (OC), in its undercarboxylated form (uOC) has been shown to influence glucose homeostasis in animal models.The aim of our study is to evaluate if the intermittent administration of 1–84 PTH could influence glucose metabolism through its anabolic action on the skeleton.We enr...

Treatment of postmenopausal osteoporosis with bisphosphonates reduces bone resorption and formation. Sclerostin, an osteocyte regulator of bone formation may be involved in these changes. Some studies have reported an increase in sclerostin associated with bisphosphonate treatment while others have reported a decrease. The aims were to determine the effect of bisphosphonates on i) circulating sclerostin and ii) PINP in postmenopausal women with osteoporosis. We studied 92 post...

Background: Vitamin D deficiency is highly prevalent and can be associated with adverse health outcomes. Few studies have evaluated the effects of daily consumption of milk fortified with a high dose of vitamin D in a large cohort of healthy postmenopausal women.Objectives: To determine the effect of daily intake of milk enriched with vitamin D (with or without fructooligosaccharides (FOS)) on vitamin D status, bone mass and cardiovascular risk factors.<...

Objectives: To examine the association of gastrointestinal (GI) events and osteoporosis (OP) therapy initiation patterns among postmenopausal women following a diagnosis of OP from a large health plan in Israel.Methods: Women aged ≥55 years were included in the analysis if they had ≥1 OP diagnosis (ICD-9 733.0X) (date for first OP diagnosis was index date), no estrogen use, no diagnosis of Paget’s disease or malignant neoplasm. OP treatm...

A Danish database initiative was established in 2003 with the purpose of evaluating patients treated with teriparatide. After the introduction in 2006 of 1–84-PTH, these patients were also included. A total of 1494 patients from 19 centers were reported to the database, until closure in 2011. The reported patients correspond to a third of all patients in Denmark receiving anabolic treatment during this time period. With regard to age and sex the reported patients do not d...

In a recent randomized controlled trial comparing vertebroplasty (VP) vs conservative treatment (CT) in patients with symptomatic vertebral fractures (VF) we observed the development of severe chronic back pain (CBP) in nearly one quarter of patients. The aim of this study was to evaluate the risk factors related to the development of CBP in these subjects.Methods: We evaluated risk factors including: visual analog scale (VAS) at baseline and during the ...

Background: Osteoporosis treatment involves several therapeutic tools, including long-term drug therapy. Subjects with chronic disorders are more likely to be non-adherent and/or non-persistent to treatment than those with other diseases. Adherence is the extent to which patients take medication as prescribed by their physicians, whereas persistence is the time from treatment initiation to discontinuation. Lack of persistence is common among subjects using oral anti-osteoporot...

Research design and methods: A characterisation of 225 European (Russian) osteoporotic postmenopausal women, treated for 2 years with amino-bisphosphonate zoledronic acid (zol), with respect to the adenosine/cytosine (A/C) rs2297480 farnesyl pyrophosphate synthase (FDPS) gene polymorphism, was carried out by PCR-based enzymatic digestion and quantitative PCR allelic discrimination on genomic DNA extracted from blood leukocytes. The association between these polymorphism genoty...

We have shown previously that TSG–6 acts as an autocrine regulator of osteoclast activity in vitro, capable of inhibiting RANKL-mediated osteoclastic bone resorption with a similar potency to OPG1,2. Thus, the TSG–6 protein has the potential to be developed as a novel treatment for osteoporosis, which is associated with excessive bone loss3.The aim of this study was to determine the therapeutic potential of the is...

Objective: We evaluated the effect of risedronate on BMD and bone turnover markers in HIV infected osteoporotic males, according to their gonadal status.Methods: 41 HIV patients treated with highly active anti-retroviral therapy (HAART) were followed for 24 months and divided into two groups: patients with osteoporosis or osteopenia with fractures (Group A, n=20) and those without (Group B, n=21). Group A and B were fur...

Ibandronate (IBN), a nitrogen-containing bisphosphonate, and eldecalcitol (ELD), an active vitamin D3 derivative, are used for osteoporosis treatment. Vitamin D3 often used in combination therapies, however, there are no reports on the effects of combined IBN and ELD treatment for osteoporosis.In this study, we examined the effects of combination treatment with IBN and ELD in aged ovariectomized rats. Eight-month-old Wistar-Imamichi...

The selective cathepsin K inhibitor odanacatib (ODN) is currently in development for the treatment of postmenopausal osteoporosis. Our goal was to evaluate the effects of ODN vs alendronate (ALN) on bone mass and strength of lumbar vertebrae (LV) in orchiectomized (ORX) rabbits, a model of male osteoporosis. Adult male rabbits (11 months old) were subjected to sham- (n=20) or ORX-surgery (n=24/group) for 7.5 months before dosing initiated. ORX animals were ra...

Eldecalcitol (ED-71; ELD), a 2β-hydroxypropyloxy derivative of 1α,25(OH)2D3, was approved to treat osteoporosis in Japan in 2011. The endothelial protective effect of vitamin D3 in osteoporosis is not clear. This study evaluated the endothelial protective effect of ELD in ovariectomized (OVX) rats.ELD (20 ng/kg) was orally administered five times a week for 4 weeks from 1 day after OVX surgery. Four weeks after surgery, flow-mediated dilation (...

Objectives: This study aims to evaluate and compare the preferences of patients and health care professionals for osteoporotic drug treatment.Materials and methods: A discrete choice experiment was conducted among patients and health care professionals (general physicians, rheumatologists, and geriatricians) in Belgium. Participants were asked to choose between two hypothetical unlabelled drug treatments (and an opt-out option) that vary in several attri...

Previous studies have demonstrated that patients with osteoporosis (OP) have a poor understanding of their bone disease and that this negatively influences treatment decisions and medication compliance. The aim of this study is to determine if there is a discrepancy between perceived and objective disease knowledge (PK and OK, respectively) in patients with OP and whether this correlates with certain patient characteristics.Design and methods: After ethi...

Many pharmacological treatments have been developed in order to prevent or treat postmenopausal osteoporosis. There is not any study in the literature comparing long-term treatments of osteoporosis. The aim of this work was to studythe effects of long-term prevention treatment with zoledronic acid (ZA) and strontium ranelate (SrR) on bone microstructure in ovariectomized rats.Sixty 6-month-old female Wistar rats were used in this study and divided into f...

Objectives: To assess safety and clinical efficacy during 1–34 parathyroid hormone treatment (1–34-PTH) in real clinical practice; to describe fracture outcome after 1–34-PTH discontinuation in real clinical practice.Methods: We performed an observational study in real clinical practice of all consecutive severe osteoporosis (sOP) patients referred to our Rheumatology Department from Feb’10 until Jan’14. All patients were referre...

Hip fractures are a major cause of burden in terms of mortality, disability, and costs. In Ireland, 3000 hip fracture occur annually and is expected to increase over the coming years1. Estimated cost of hip fractures is &z.euro;14 300/admission2. Outpatient non-attendance is a source of inefficiency, wasting time, resources and lengthens waiting lists. Non attendees have a significant negative impact on productivity, their own care and resources. In 2008,...

Purpose: This combined qualitative and quantitative study aimed to investigate women’s personal reasons for and choices to decline the screening for osteoporosis. The ROSE study is a randomized prospective population-based trial investigating the efficacy of a screening program to prevent fractures in women aged 65–80 years.Methods: A triangulated approach combining data from interviews and questionnaire. 7020 questionnaires from the screening ...

Objective: The purpose of this study was to compare the efficacy of raloxifene (RLX) 60 mg daily, vitamin D (VD) 200 IU daily, and alendronate (ALN) 35 mg once weekly on bone mineral density (BMD) of lumbar spine (L) and total femur (F) in postmenopausal women with osteoporosis, and the effects of the osteoporosis risk factors on BMDs and these treatments.Design and methods: The subjects were 242 postmenopausal Japanese women aged 48–87 years (mean ...

Objectives: To determine whether kinds of implants would influence on the radiologic outcomes in the treatment of osteoporotic intertrochanteric fractures.Materials and methods: In this retrospective study, radiologic outcomes of 151 patients with unstable osteoporotic intertrochanteric fractures undergoing surgical treatments were compared based on the types of fixation implants as follows: PFNA (53 cases, group 1), gamma nail 3 (31 cases, group 2), CHS...

Objective: This multi-objective prospective study (MUSIC-OS) is intended to examine treatment patterns, occurrence of gastrointestinal (GI) complications and clinical and health outcomes in post-menopausal osteoporotic (OP) women in Europe and Canada. Surveys were administered to both physicians and patients as part of the MUSIC-OS study to document reasons for undertreatment in OP from both physician and patient perspectives.Materials and methods: A phy...

Introduction: Effective treatment of postmenopausal osteoporosis (PMO) is frequently compromised by poor adherence to short-term (≤1-monthly) medications. Aim of this study is to investigate the effect of parenteral ibandronate (IBN) compared to denosumab in a cohort of IBN pretreated PMO patients.Methods: In a retrospective analysis, a total of 808 women were treated with quarterly 3 mg IBN injections for 27+3 months and were regularly mo...

Long-term use of pharmacological treatments of osteoporosis is currently a controversial subject within the scientific community.The aim of this work was to study the effects produced by a preventive long duration treatment of strontium ranelate and zoledronic acid on bone mass and remodelling when they are administered to ovariectomized rats.Sixty female albino Wistar rats were divided into four groups (n=15): SHAM group ...

Introduction: Clinical practice guidelines recommend a daily intake of calcium of 1-1, 5 g for posmenopausical osteoporosis. However, giving the possible adverse effects of calcium supplements, their use remains controversial.Aims: Validate the dietary assessment of calcium. Evaluate the degree of compliance of the medical advice and discuss the adequacy of prescribing calcium supplements.Patients and methods: Sample cohort compris...

Three oral bisphosphonates ibandronate, alendronate, and risedronate are commonly used for the treatment of osteoporosis but they have not previously been compared in the same study. Our aim was to identify determinants of change in bone turnover markers (BTM) in response to these bisphosphonates in a 2-year randomised parallel group trial. We recruited 171 postmenopausal osteoporotic women (<85 years) who were randomised to receive ibandronate (150 mg monthly), alendronat...

Background: It is known that one of the features of rheumatoid arthritis (RA) is a generalized bone loss, therefore important tasks for the physician are timely evaluating of the risk of fractures and approving osteoporosis treatment in patients with RA.Objectives: Through the Programme of the Russian Association of Rheumatology for the diagnosis, prevention and treatment osteoporosis (OP) in patients with RA we evaluated the 10 year probability of major...

The therapy of osteoporosis in patients with end organ failure and after the transplantation (Tx) becomes more frequent problem with the better patients and graft survival rates. Moreover some of these patients have impaired renal function and therefore cannot use bisphosphonates. The supplementation therapy with calcium and/or vitamin D is frequently not sufficient to improve bone mass. The possible innovative therapy is Denosumab (Prolia inj.) - MAB to RANK, which is not con...

Background: Atypical fractures (AF) of femoral shaft have distinct radiologic features and are probably related to prolonged bisphosphonate (BP) exposure. They are currently considered to be insufficiency fractures occurring in osteoporotic bone. After initial damage, the repair process calls for accelerated remodeling, but the later is prevented by BP accumulation on the remodeling site. Thus, the fracture expands instead of healing. The management is not postulated, but anab...

Introduction: Teriparatide is a potent anabolic drug that has demonstrated efficacy on fracture risk reduction in women with severe postmenopausal osteoporosis. Denosumab, designed to inhibit RANKL (RANK ligand), is a fully human MAB for the treatment of osteoporosis. BMD changes, measured by DXA, is an established tool for monitoring the effects of anti-osteoporotic therapy. Our purpose is to compare teriparatide vs denosumab efficacy on hip BMD variations, in postmenopausal ...

Introduction and aim: Many patients with osteoporosis are elderly and oral health is an important aspect of patient care especially in patients on bisphosphonates. Our aim was to determine oral health attitudes and practices in patients with osteoporosis receiving bisphosphonates.Methods: A questionnaire study was conducted after informed consent on cognitively intact patients diagnosed with osteoporosis who were attending hospital Osteoporosis clinic an...

Alendronate is one of the most popular anti-resorptive drugs and widely used to treat osteoporotic patients in the world. In Japan, alendronate oral jelly (ALN-J) as a new formulation was launched in 2013. Dissolution test and bioequivalence study were performed between ALN-J and alendronate oral weekly tablet (ALN-T), and bioequivalence of both drugs was approved. Dosage and administration of ALN-J is the same as ALN-T. Moreover, ALN-J has special features of easy swallowing ...

According various guidelines the basic recommendation in prevention and treatment of postmenopausal osteoporosis (PMO) is adequate intake of calcium (1000– 1300 mg/day) and vitamin D (800–1000 IU/day).Aim: To determine the intake dose of calcium and also the vitamin D saturation in women treated for PMO.Patients and methods: 465 women with PMO, divided into two groups: patients with newly diagnosed osteoporosis (n</em...

Background: Osteoporotic fractures are a major cause of disability and results in extensive utilization of health care resources. The history of previous fractures increases the risk for future fragility fractures.Subject: To describe the diagnostic therapeutic protocol of our tertiary care clinic dedicated to the osteoporosis (OP) treatment. To estimate the use of effective therapies for OP in those patients at highest risk for future fracture.<p cl...

Objectives: Clinicians practicing in long-term care (LTC) face unique challenges caring for frail elderly individuals including multiple co-morbidities, polypharmacy, and end of life care, and practice guidelines typically do not address this population. Guidance regarding the management of osteoporosis and fracture prevention in LTC, a high-risk population, is needed.Materials and methods: A survey of LTC physicians informed key questions and outcomes, ...

There are few cases of pregnancy described in which the fetus was exposed to some bisphosphonates, but not ibandronate to our knowledge. Meanwhile, ibandronate has a high protein binding rate (87%) and short tissue’s half-life (24 days) and might be a less potentially harmful drug in the event of pregnancy.A 23-year-old woman was admitted to our hospital with evident ACTH-dependent Cushing’s syndrome CS (24 h urinary free cortisol – 2413 n...

Denosumab (DNMB) is an effective treatment for osteoporosis with antiresorptive effect that has demonstrated to increase the bone mass and reduces the incidence of both vertebral and nonvertebral fractures in randomized controlled trials (RCTs).Objectives: To confirm that this drug is actually effective in our experience into daily clinical practice as well.Material and methods: 30 postmenopausal women, mean age 71 years (r</em...

Introduction: Denosumab monoclonal antibody approved for Osteoporosis’s treatment in Europe union and U.S.A. Dose of 60 mg every 6 months reduces the risk of vertebral, non vertebral and hip fractures. What is more increases BMDMaterial and methods: Descriptive observational study with densitometric characterisques and risk factors of 64 patients in Osteoporosis unit of HGUG Marañón from November 2011 to December 2013. Analyzing occurrence...

Background: Denosumab is licensed for the treatment of osteoporosis in the UK. Guidance issued by NICE and SMC in indicated that Denosumab may be used in the treatment of patients with postmenopausal osteoporosis who are unsuitable for other treatments. Here we have reviewed the clinical characteristics of patients treated within a secondary care referral centre adverse events encountered during treatment.Methods: We reviewed data from 75 consecutive pat...

Objectives: To assess the pharmacological management of osteoporosis in a cohort of hospitalized medical in-patients within a Welsh district general hospital.Materials and methods: We collected data using medical records on a structured proforma as a point prevalence study targeting medical inpatients aged fifty and above in an admitted hospital cohort.Results: Out of the 117 patients, 88 (75.21%) of them had greater than three ris...

It is well known that osteoporotic fragility fractures are an important risk factor for subsequent new vertebral and non-vertebral fractures. Many countries published recommendations to prevent fractures. Also in Italy the Minister of the Health highlighted the importance to prevent osteoporosis and the subsequent fractures, without practical instructions on the management of patients with fragility fractures in the daily clinical practice. Up to date there is no standardized ...

Introduction: Denosumab, a fully human monoclonal antibody to RANK ligand, effectively reduces bone resorption by inhibiting RANK-L binding to RANK. We aimed to evaluate the efficacy of denosumab in post-menopausal women, by monitoring the evolution of different parameters of bone health: T-score, morphometry, osteocalcin and β-Ctx.Methods: A 34 women with severe postmenopausal osteoporosis, characterized by multiple vertebral fractures wer...

Objectives: To confirm effect of intravenous treatment with ibandronate every three months in common population of postmenopausal women.Methods: Patients with postmenopausal osteoporosis, who fulfil ACR criteria for postmenopausal osteoporosis and were treated with intravenous ibandronate for two years, underwent DEXA examination.Results: A 50 women suffering from postmenopausal osteoporosis were treated with ibandronate i.v. every...

Objective: This study evaluated the differences in physical performance and risk of fall in old oldest people affected by severe osteoporosis.Methods: The subjects were all ≥85:45 women (mean age 88±3) and six men (mean age 88±2) affected by severe osteoporosis. In seven women and one man we discovered a new spinal fracture after treatment. Thirty-eight women and three men had multiple spinal fractures (>3). The subjects were prescrib...

Long-term bisphosphonate (BP) therapy can be complicated by atypical femoral fracture (AFF). A positive effect of teriparatide (TPTD) has been suggested.A woman (A, 81) with densitometric OP was put on alendronate (ALN) from 1997 until 2006, substituted by ibandronate (IBA), with an increase in FN-BMD of 6.6%. In August 2010, a fall from her standing height provoked a right transverse femoral fracture, which was operated. She was weaned from BP therapy. ...

Transient osteoporosis of hip (TOH) is a spontaneous resolving skeletal disorder characterized by sudden onset of severe pain which resolves within 6–12 months. It is seen more commonly in middle aged men, though also seen in third trimester of pregnancy. MRI is the main diagnostic tool. It is idiopathic in nature.We present a case report of a young adult male who presented with migratory transient osteoporosis of both hip joints separated by a peri...

Abaloparatide (BA058) is a synthetic analog of PTHrP1–34 which greatly increases bone mass and bone strength with preservation of normal bone quality in animal models of osteoporosis. Daily s.c. abaloparatide (ABLSC) at doses of up to 80 μg daily in postmenopausal women with osteoporosis for up to 48 weeks were associated with increases in spine and femoral neck BMD of up to 12.9 and 4.1% respectively and good safety and tolerability. The increa...

Abaloparatide (ABL) is a novel analog of hPTHrP (1–34) in clinical development for treatment of osteoporosis. This study evaluated the long-term effects of ABL on BMD and bone strength in aged osteopenic, ovariectomized (OVX) monkeys. Four groups of ≥9-year-old female cynomolgus monkeys underwent OVX and one group underwent Sham surgery. After a 9-month bone depletion period, increases in bone markers and decreases in BMD by DXA and pQCT were observed for OVX groups...

Intermittent PTH reduces vertebral fractures risk in osteoporotic patients. The mechanisms trough which PTH acts are not completely understood, it has been observed to activate Wnt pathways in osteoblasts (OBs). Activation of this pathway induces OB proliferation, differentiation and prevents apoptosis. Recently increased expression of Wnt10b by T cells during intermittent PTH, and no increase during continuous PTH has been demonstrated in mice.In order to evaluate if PTH incr...

Bone strength is influenced by cortical thickness, area, mass and porosity, all of which contribute to nonvertebral fracture risk. Cortical porosity is one parameter of structural decay associated with bone fragility. This is caused by unbalanced and accelerated remodelling of Haversian units which enlarge, coalesce and fragment the cortex. Antiresorptive therapies will limit progression of cortical porosity; reducing existing porosity would be a goal for those already at incr...

In clinical studies, denosumab (DMAb) administration up to 8 years is associated with continued increases in bone mineral density (BMD) and low fracture incidence despite persistently low bone turnover markers and limited iliac crest tetracycline labelling (Papapoulos 2013). We tested the hypothesis that, with persistently low bone remodelling, BMD increases may result from a non-remodelling dependent mechanism to accrue bone matrix. We examined the fluorochrome labelling patt...

Patients with osteoporosis require treatment with therapies that reduce the risk of fracture which at the spine is significantly influenced by bone microarchitecture. Quantitative computed tomography (QCT) and dual X-ray absorptiometry (DXA) allow measurement of bone mineral density (BMD), a known indicator of fracture risk. Trabecular bone score (TBS) is a novel gray-level measurement derived from spine DXA image texture that is related to microarchitecture and associates wit...

Low bone mineral density (BMD) is an important and modifiable risk factor for fracture in postmenopausal women with osteoporosis. Denosumab (DMAb) shows a stronger relationship between BMD increases and antifracture efficacy than oral bisphosphonate (BP) therapies. Subjects who remain at higher risk of fracture despite current BP therapy need treatment. In two studies, DMAb significantly increased BMD and decreased bone turnover markers vs a BP (ibandronate (IBN) or risedronat...

Objective: I.m. injections with Botox (BTX) leads to a paralysis of the muscles, resulting in a rapid loss of muscle and bone mass (disuse osteoporosis). Adipocytes and osteoblasts derive from the same mesenchymal stem cell, and commitment to one linage represses commitment to the other. Furthermore, the existence of a close communication between bone cells and endothelial cells is widely accepted.The purpose of the study was to quantify the changes in a...

Bisphosphonates (BPs) including alendronate (ALN) are the most widely prescribed therapy for post-menopausal osteoporosis. Despite their overall excellent safety record and efficacy in reducing fractures, concerns have been expressed lately regarding potential detrimental effects due to prolonged bone turnover reduction, although no definite cause–effect relationship has been established to date. The purpose of the present study was to determine bone material quality by R...

Objective: To identify predictors of inadequate response to oral bisphosphonate therapy, defined as the incidence of &gE;2 fractures while on treatment among incident oral bisphosphonate users with high refill compliance (&gE;80%).Material and methods: Data from computerized records and pharmacy invoices were obtained from SIDIAP (Catalonia, E) and Danish Health Registries (DK) for all incident users of oral bisphosphonates in 2006–2007 and 2000&#15...

We previously demonstrated that an isocaloric low protein diet attenuates the bone anabolic response to GH. Whether such a dietary manipulation could affect the bone anabolic effects of PTH was assessed. We studied 6-month-old female rats pair fed with isocaloric diets with a low protein (2.5% casein, LP) or normal protein content (15% casein, NP) for 2 weeks. Then, the animals were treated with 5 or 40 μg/kg recombinant human amino-terminal fragment PTH(1–34) (PTH-5...